Glenmark Pharmaceuticals U.S. > News

News

Press Releases

Get access to Glenmark information and resources for stories in development.
Find recent and archived press releases.

Glenmark receives tentative ANDA approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg and 150 mg

April 19, 2017

Glenmark Pharmaceuticals receives tentative ANDA approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg and 150 mg

April 19, 2017

Glenmark receives ANDA approval for Fenofibrate Capsules USP, 67 mg, 134 mg and 200 mg

April 10, 2017

Glenmark Pharmaceuticals receives ANDA approval for Fenofibrate Capsules USP, 67 mg, 134 mg and 200 mg

April 10, 2017

Glenmark receives tentative ANDA approval for Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg and 100 mg

March 31, 2017

News

Search Result :-

Is an investigational new drug that has not been approved for commercial distribution in the United States.

April 19, 2017
Glenmark receives tentative ANDA approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg and 150 mg

April 19, 2017
Glenmark Pharmaceuticals receives tentative ANDA approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg and 150 mg

April 10, 2017
Glenmark receives ANDA approval for Fenofibrate Capsules USP, 67 mg, 134 mg and 200 mg

April 10, 2017
Glenmark Pharmaceuticals receives ANDA approval for Fenofibrate Capsules USP, 67 mg, 134 mg and 200 mg

March 31, 2017
Glenmark receives tentative ANDA approval for Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg and 100 mg

US Media Contact

For media inquiries only, please contact Corporate Communications.
uscomms@glenmarkpharma.com

Investor Relations

For more information on Glenmark Pharmaceuticals Ltd., including Annual Reports, Analyst Presentations and Financial Results, please visit our Investor Relations.

POTASSIUM CHLORIDE EXTENDED RELEASE CAPSULES 750mg RECALL REIMBURSEMENT POLICY

Over-the-counter (OTC)

ACCESSIBLE PRODUCTS

Who We Are

Injectables

OUR GROWING LINE